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ABSTRACT
Introduction Preeclampsia (PE) is a pregnancy-speciﬁc syndrome associated with adverse maternal and fetal
outcomes. Patient-speciﬁc risks based on angiogenic factors might better categorize those who might have a severe
adverse outcome.
Methods Women evaluated for suspected PE at a tertiary hospital (2009–2012) had pregnancy outcomes categorized
as ‘referent’ or ‘severe’, based solely on maternal/fetal ﬁndings. Outcomes that may have been inﬂuenced by a PE
diagnosis were considered ‘unclassiﬁed’. Soluble fms-like tyrosine kinase (sFlt1) and placental growth factor (PlGF)
were subjected to bivariate discriminant modeling, allowing patient-speciﬁc risks to be assigned for severe outcomes.
Results Three hundred twenty-eight singleton pregnancies presented at ≤34.0weeks’ gestation. sFlt1 and PlGF levels
were adjusted for gestational age. Risks above 5 : 1 (10-fold over background) occurred in 77% of severe (95% CI 66 to
87%) and 0.7% of referent (95% CI <0.1 to 3.8%) outcomes. Positive likelihood ratios for the modeling and validation
datasets were 19 (95% CI 6.2–58) and 15 (95% CI 5.8–40) fold, respectively.
Conclusions This validated model assigns patient-speciﬁc risks of any severe outcome among women attending PE triage.
In practice, women with high risks would receive close surveillance with the added potential for reducing unnecessary
preterm deliveries among remaining women. © 2015 The Authors. Prenatal Diagnosis published by JohnWiley & Sons Ltd.
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INTRODUCTION
Preeclampsia (PE), a syndrome characterized by hypertension
and proteinuria, is suspected in 10% of pregnancies but
conﬁrmed in only 2 to 3%.1 In developed countries, PE is a
leading cause of medically indicated preterm births.2 Annually,
a half million US babies are delivered before 37weeks’
gestation; 25% are induced for medical or obstetric indications.
Nearly half are attributable to a PE diagnosis, and some may be
avoidable. Our current clinical3 and laboratory tests do not
accurately predict adverse outcomes,4,5 and confusion arises
from underlying diseases that mimic PE.6–9
The American Congress of Obstetricians and Gynecologists
(ACOG) endorses immediate delivery in women with PE at and
beyond 37weeks.10 Expectant management is recommended
when symptoms occur earlier, with the goal of reaching 34 weeks
among patients with severe features.10 Current clinical and
laboratory criteria cannot reliably distinguish between women
requiring early induced delivery as a result of imminent severe
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maternal/fetal morbidity and those that can be managed safely
to a later date.11,12 Thus, providers may over-utilize laboratory,
ultrasound and clinical services, delivering some pregnancies
earlier than necessary with potential preterm delivery
complications. Accurately determining the risk of serious
outcomes among women evaluated for PE could reduce the rate
of preterm delivery, improve resource allocation and reduce
spending.13 It would also deﬁne a group with high risks that
could be candidates for newer potential treatment modalities.14
A decade ago, alterations in circulating soluble fms-like
tyrosine kinase (sFlt1) and placental growth factor (PlGF) were
observed to be associated with PE.15–17 Circulating anti-
angiogenic protein sFlt1 is elevated, while free concentrations
of pro-angiogenic protein PlGF are reduced. These changes
occur before clinically overt ﬁndings.18–20 The combination of
sFlt1 and PlGF has high sensitivity and speciﬁcity to predict
certain adverse outcomes.19–21 Preliminary studies have
explored the clinical validity of these markers among women
with suspected PE.22–24 We reported that over 95% of selected
adverse outcomes in women with suspected preterm PE were
associated with signiﬁcant abnormalities in angiogenic
factors.23 Rates of adverse outcomes among women with
sFlt1/PlGF ratios <85 were low and generally unrelated to
PE,25 and others have reported similar ﬁndings.22,24,26,27
However, many such studies deﬁned adverse outcomes with
direct ties to the diagnosis of PE or excluded certain adverse
outcomes not related to PE or the angiogenic factors. Soluble
endoglin (sEng), another anti-angiogenic protein, is also
associated with PE-related adverse outcomes.28
In addition to the varying deﬁnitions of severe outcome, the
use of an sFlt1/PlGF cutoff of ≥85 as a predictor has potential
drawbacks based on implicit assumptions: (1) The relationship
between sFlt1 and PlGF and adverse outcomes is constant by
gestational age, (2) the strength of association is similar for
both markers, (3) absolute levels of the two markers are
unimportant, (4) confounding variables inﬂuence each marker
in a similar way, (5) the cutoff of 85 is optimal, (6) prior risk
factors are unimportant and (7) a categorical result (positive/
negative) is sufﬁcient for clinical decision-making. The present
study addresses the issue of optimizing the interpretation of
these angiogenic factors for prediction of impending severe
adverse pregnancy outcomes that are deﬁned using only
maternal and fetal outcomes that are both comprehensive
and not related to the diagnosis of PE. The setting is for ‘high
risk’ women being evaluated for PE in triage; the results,
therefore, may not be applicable to screening in the general
population. The intent of such testing is to repeat testing every
2weeks and update risk estimates.
METHODS
Study participants
Women presenting at the obstetric triage unit for PE evaluation
at Beth Israel Deaconess Medical Center (BIDMC) between
July 2009 and June 2012 were eligible (BIDMC approval
2009P-000084). Women provided written informed consent.
Subjects presenting before October 2010 have been reported
earlier, but a different deﬁnition of adverse outcome was
used.23,28 Current analyses were limited to singleton
pregnancies ﬁrst evaluated at ≤34.0weeks with angiogenic
marker measurements, pregnancy outcomes and delivery
information. The majority of pregnancies seen at triage were
ﬁrst evaluated after 34.0weeks, and these were not considered
in our analyses. Hypertensive disorders of pregnancy (chronic,
gestational hypertension, PE and superimposed PE) were
deﬁned according to the 2002 ACOG Bulletin29 with minor
modiﬁcations as deﬁned previously.23,25
Relevant ﬁndings for the woman and the fetus
Clinical ﬁndings, results of physical examinations, blood
pressures, standard laboratory tests and ultrasound ﬁndings
within 2 weeks of the initial presentation were stored along
with information from subsequent outpatient and inpatient
visits.23,25 Table 1 lists maternal ﬁndings used to classify
pregnancy outcomes. Fetal and neonatal ﬁndings (e.g. gestational
age at delivery, birth weight, neonatal death) were abstracted
from patient charts and were also used to classify outcomes
(Table 1).
Table 1 Relevant maternal and fetal ﬁndings and the deﬁnition of
three pregnancy outcome categories
Code
Within
2 weeksa Finding
Maternal
M0 No None of the following maternal ﬁndings
M1 Yes Severe hypertension (BP ≥ 160/110)
M2 Yes Elevated liver function test(s) (LFT)
M3 Yes Disseminated intravascular coagulation (DIC)
M4 No Placental abruption
M5 Yes Pulmonary edema
M6 Yes Cerebral hemorrhage
M7 Yes Maternal death
M8 Yes Eclampsia
M9 Yes Acute renal failure
M10 No HELLP syndrome
Fetal
F0 No None of the following fetal ﬁndings
F1 No Small for given gestational age (<5th centile)
F2 No Pre-term delivery (≤34.0 weeks)
F3 No Very pre-term delivery (≤32.0 weeks)
F4 No Neonatal death
Pregnancy outcome
Referent — ‘Normal’ group – (M0 AND F0 throughout
pregnancy)
Severe — Severe adverse outcome – (M3 through M10) OR (F3
through F4) OR (F1 AND F2 AND BP ≥ 140/90)
Unclassiﬁed — All remaining pregnancies
aThe ﬁnding was recorded within 14 days following the initial presentation at the
triage clinic. In practice, the intent is for women to be retested and reinterpreted every
2 weeks.
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Sample collection and measurement of angiogenic factors
Residual blood samples from clinical testing were stored at 4 °C
for 48 h, collected and centrifuged at 3000 rpm for 10min.
Plasma was aliquoted and stored at 80 °C; these analytes are
stable for 10 years.18 Samples had not been thawed prior to
testing. Testing for sFlt1 and PlGF on samples collected through
October 2010 was performed on an automated platform (Elecys,
Roche Diagnostics, Indianapolis, IN).23,30 Remaining samples
(through June 2012) were tested on the same platform at
BIDMC. Inter-assay coefﬁcients of variation for sFlt1 and PlGF
were 2.6 to 3.0% and 2.0 to 2.4%, respectively. Laboratory
personnel were blinded to clinical information, and physicians
were unaware of test results.
Deﬁnition of three pregnancy outcome categories
Samples were obtained prospectively, but angiogenic factors were
tested after delivery. Thus, the women were subject to the current
care standards. A ‘referent’ category included all pregnancies with
no adverse maternal or fetal ﬁndings (Table 1). Importantly, PE
was not considered as a maternal ﬁnding. This referent group
was used to deﬁne the gestational age relationships for angiogenic
factors and to deﬁne the false positive rate. The ‘severe’ category
contained those pregnancies with an adverse outcome for the
mother, fetus or both (Table 1), usually occurring within the next
2weeks. This group was used to determine the detection rate. Our
aim was to avoid arbitrary classiﬁcations that would be biased
toward abnormal angiogenic factor measurements or toward a
PE diagnosis. Delivery prior to 32.0weeks was hypothesized to
be because of severe disease with accompanying complications.
Remaining pregnancies were placed in a third heterogeneous
‘unclassiﬁed’ category with the assumption that a PE diagnosis
may have inﬂuenced delivery in our observational study. The 2-
week limit on measuring outcomes reﬂects the intent that such
testing be repeated in these pregnancies every 2 weeks until they
reach 34.0 weeks’ gestation.
Statistical analysis
Included pregnancies were randomly assigned to a modeling or
validation subset. Within the modeling dataset, measurements
from referent samples were used to derive median levels between
20 and 34weeks’ gestation. Modeling was based on validated
approaches used for prenatal Down syndrome screening.31 Assay
results were converted to multiples of the median (MoM) and
weight adjusted.32 Data were further examined to determine
whether parity, smoking or other factors might inﬂuence
measurements. Bivariate discriminant analysis was used tomodel
the ability of angiogenic factors to differentiate severe and
referent outcomes. The discriminant function provided the
likelihood of a pregnancy being in a given outcome category.
The risk of a severe outcome was calibrated using the dataset’s
observed risk of a severe outcome (e.g. the model’s average risk
equals risk in the dataset). Risks were arbitrarily stratiﬁed into
‘low’ (more than a 10-fold reduction from baseline), ‘high’ (more
than a 10-fold increase) or ‘moderate’ (all intervening risks)
groups. Individual risks were capped at 100-fold increase or
decrease. This preliminary model was then applied to the
validation dataset and its performance compared. If the
performance was consistent in the two datasets, a ﬁnal model
would be produced using the entire cohort.
Approximately 15 pregnancies with severe outcomes
are required for each of the independent factors considered
(i.e. 30 severe outcomes in the modeling and validation
datasets for sFlt-1 and PlGF), for a total of 60 cases.
Approximately 30% of our originally published cohort presented
≤34.0weeks, and adverse outcomes occur in about 30%. Thus,
about 670 women (60/0.3/0.3) attending a PE triage clinic would
be sufﬁcient for reliablemodeling. The entire cohort consisted of
1141 evaluated women, but this included twin pregnancies and
multiple enrollments for the same woman, along with many
women presenting after 34weeks’ gestation. Thus, the entire
cohort would be needed for the analyses.
RESULTS
Creating the datasets
Table 1 shows how maternal and fetal ﬁndings deﬁne three
outcome categories. The ﬁndings do not include diagnosis of PE
or relate to whether the outcome might be related to angiogenic
abnormality. Figure 1 shows that 328 of 1141 women (29%)
enrolled ≤34.0weeks of gestation and had a singleton pregnancy.
These were allocated into the modeling (N=163) and validation
(N=165) datasets with approximately equal numbers in each of
the outcome categories. Demographic characteristics in the two
datasets did not differ (Supplemental Data Table 1).
Converting to multiples of the median (MoM)
sFlt1 and PlGF measurements from referent pregnancies in the
modeling dataset (N=69) were used to compute medians
between 20 and 34weeks (Figure 2) that were used to convert
each woman’s individual analyte measurements into MoM levels.
Potential covariates of angiogenic factors
Laboratory results expressed as MoM were examined against
potential covariates (Supplemental Data Table 2) using regression
analysis. In referent pregnancies, maternal weight had a
signiﬁcant negative association with sFlt1 (p=0.037) and PlGF
(p=0.0056) and the levels were adjusted using a ﬁtted reciprocal
weight equation. The sFlt1/PlGF ratio was also signiﬁcantly
associated with maternal weight but was not adjusted. For
primiparous pregnancies, sFlt1 and the ratio tended to be higher
(p=0.16, p=0.19, respectively), but only the ratio reached
statistical signiﬁcance (p=0.017, Supplemental Table 2). The
corresponding levels for PlGF were signiﬁcantly lower
(p=0.034). Both sFlt1 and PlGF were adjusted for parity. Smoking
and maternal age were not strongly related to any of the analyte
levels, and no adjustments were made.
Bivariate analyses of markers
Figure 3 shows the bivariate relationships for sFlt1, PlGF and the
ratio, among women in the referent and severe outcome
categories. In general, within-outcome correlations between
markers were low (r< 0.4 (except for PlGF and the sFlt1/PlGF
ratio where the correlations were relatively high (r= 0.56 and
0.73 in referent and severe categories, respectively). The relative
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independence of sFlt1 and PlGF suggested that combining the
two would improve testing over one or the other.
Developing the model
The model relied on weight- and parity-adjusted sFlt1 and
PlGF MoM levels with the outcome (referent or severe) as the
dependent variable. Population risk, expressed as odds of a
severe outcome, was 1 : 2 (33%). Figure 4A shows the patient
speciﬁc risks (x-axis) versus the gestational age at delivery in
the modeling dataset. All 36 severe outcomes occurred at or
prior to 37.0weeks. Of these, 27 (75%) were classiﬁed as high
risk (≥4.6 : 1), 4 (11%) as low risk (<1 : 20) and the remaining 5
(14%) as moderate risk. The four severe outcomes classiﬁed
as low risk by our model included two cases of acute renal
failure (patients ID #164 and #328, refer to Supplemental
Tables 3 and 4), a delivery prior to 32weeks of gestation
(#234) and a neonatal death (#33). All 69 pregnancies in the
referent category, by deﬁnition, delivered after 37.0weeks. Of
these, the model classiﬁed 59 (86%) as low risk, 9 (13%) as
moderate risk and 1 (1%) as high risk (#307, normal term
delivery with BP 143/105). The observed (and median
assigned) odds for the high, moderate and low risk groups were
26 : 1 (40 : 1), 1 : 2 (1 : 7) and 1 : 15 (1 : 200). Using a lower risk
cutoff of 1 : 2, detection of adverse outcomes improved from
75 to 83%, but the false positives increased from 1 to 4%.
Applying the sFlt1 and PlGF model to the validation dataset
The model derived in the ﬁrst dataset was then applied to the
separate validation dataset with 35 severe and 74 referent
pregnancies (Figure 4B). In the high, moderate and low risk
categories, the observed numbers of severe to referent
pregnancies were 25 : 0, 7 : 18 and 3 : 56, respectively. The three
outcomes classiﬁed as severe but assigned low risk included
one acute renal failure (#185), one placental abruption (#166)
and one delivery occurring at 29weeks (#93). Using a lower risk
cutoff of 1 : 2, detection was 83% with a 5% false positive rate.
Using a 5 : 1 cutoff, detection was 71%, with a 0% false positive
rate. The positive likelihood ratios for the modeling and
validation datasets at the 1 : 2 cutoff levels were 19 (95% CI
6.2–58) and 15 (95% CI 5.8–40), respectively. At the cutoff level
of 5 : 1, the likelihood ratios were 51 (95% CI 7.3–362) and >52
(87.4 to 374), respectively (p =NS, one false positive was
assumed to allow for computations).
Combining the two datasets
Having found similar detection and false positive rates in the
two datasets, we created a combined model, based on the total
cohort. The revised medians (Supplemental Figure 1) and
adjustment factors were nearly identical. This new model also
accounted for the association of weight with severe outcomes.
The risk of a severe outcome in women weighing ≥170 lb was
signiﬁcantly lower (OR=0.37, 95% CI 0.17 to 0.83, p= 0.011) than
that in lighter weight women (Supplemental Table 2). This was
accounted for by multiplying patient-speciﬁc prior risks by
1.99 and 0.82, in lighter and heavier weight women, respectively.
The risk of a severe outcome was lower in multiparous women
(OR= 0.53, 95% CI 0.26 to 1.10, p = 0.090). Although not
statistically signiﬁcant, we chose to use our observed multipliers
of 1.24 and 0.81 for prima and multi parity, respectively, as a
result of this well-known association. The risks from the original
dataset and the combined cohort were highly correlated
(r2 = 0.96, Supplemental Figure 2). The observed odds (severe :
referent) in the high, intermediate and low risk groups were
55 : 1, 8 : 31 and 8 : 111, respectively (Figure 4C, Supplemental
Figure 1 Deﬁning the study datasets and pregnancy outcomes. Women were excluded, if initial visit was after 34.0weeks’ gestation, records
indicated multiple gestations, data were from a subsequent enrollment, or records had important missing data. A total of 328 unique women
attending the clinic and enrolling prior to 34weeks of gestation were randomized into a modeling (163) or validation (165) dataset. The last
line shows the numbers of women in the three outcome categories (referent, severe and unclassiﬁed), as deﬁned in Methods. The model was
designed to differentiate between pregnancies in the referent population and those having a severe adverse outcome
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Data, Table 3). Using the lower risk cutoff of 1 : 2, detection was
86% with a 4% false positive rate. Using the 5 : 1 risk cutoff,
detection was 77%, with a 1% false positive rate. These rates
were not signiﬁcantly different from the original modeling
estimates indicating a robust model. Selected demographic,
clinical and modeling results for patients are available
(Supplemental Table 4). For research purposes, a spreadsheet
was created to calculate patient-speciﬁc risks (screenshot
available as Supplemental Data Figure 3).
Comparing the performance of the risk model with the sFlt1/
PlGF ratio
Because the bivariate model and sFlt1/PlGF ratio are based on
the same two angiogenic factors, test performance is expected
to be similar (Figure 5). Among the 52 severe outcomes with
elevated ratios, all were assigned high risks by the model.
Among the remaining 19 severe outcomes with negative
sFlt1/PlGF ratios, three, eight and eight had high, moderate
and low assigned risks. Using the higher risk 5 : 1 cutoff, the
detection and false positive rates for the model were 77 and
1%, as compared with 73 and 1% for the sFlt/PlGF ratio, alone
(cutoff of 85).
Results in the unclassiﬁed outcome group
It was not possible to classify 114 pregnancies delivering
between 34.1 and 37weeks’ gestation (Figure 1). It is likely that
some portion was delivered early because of a diagnosis of PE,
but it was not possible to determine which would have, in the
absence of intervention, resulting in a severe or referent
outcome. The model classiﬁed 51 of these pregnancies (45%)
as low risk, and delivery occurred at an average of 34.9weeks
(ﬁve missing information, Supplemental Figure 4). Eight of
the 51 (16%) had a diagnosis of PE. We assigned high risk to
29 pregnancies (25%), with delivery at an average of 33.3weeks.
Twenty (69%) had a PE diagnosis. Among the remaining 34
(30%) pregnancies with moderate risk, delivery occurred at an
intermediate 34.6weeks and 8 (24%) had a PE diagnosis.
Overall, there was a positive association between assigned risk
category and diagnosis of PE (X2 test of trend, p< 0.001) as well
as between assigned risk and earlier delivery (log linear
regression, test of slope = 0, p< 0.001).
Usefulness of angiogenic factors: an example of renal failure
In our dataset, renal failure was diagnosed in seven
pregnancies (Supplemental Data Table 5). Four had reduced
risks of severe outcome (range 1 : 217 to 1 : 3) and negative
sFlt1/PlGF ratios (0.5 to 16). The other three had increased
risks (1 : 1 to 6 : 1). All three had negative but relatively high
sFlt1/PlGF ratios (39 to 63). The four pregnancies with low risks
Figure 3 Bivariate comparison of angiogenic factor measurements in women with pregnancy outcomes classiﬁed as referent (69) or severe
(36) from the modeling dataset. These ﬁgures show the relationships between two angiogenic factors (sFlt1 and PlGF) expressed as
multiples of the median (MoM) that were selected for model development and the sFlt1/PlGF ratio. Values in pregnancies with severe outcomes
are shown as small ﬁlled circles, while corresponding values in the referent pregnancies are shown as large open circles; for Figures 3A
through 3C, the r-squared values in the referent and severe outcome groups are 0.02903, 0.4513; 0.3048, 0.2780; and 0.5649, 0.7341
Figure 2 Gestational age-speciﬁc medians for SFlt1 and PlGF. These
results are from the 69 referent women in the modeling dataset. The x-
axis shows the gestational age at sample collection, up to 34.0weeks
of gestation. The logarithmic y-axes show sFlt1 and PlGF results. Solid
lines/curves show the ﬁtted regression equation indicating the reference
(median) value by decimal gestational age (dGA). These equations are
the following: median_sFlt1=10((0.0067947653*dGA^2) + (0.37004674*dGA)
+ 8.138) and median_PlGF=10((0.011431524*dGA) + 2.374)
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delivered later (average 32 vs 29weeks) had higher APGAR
scores, and blood pressures were lower (average 165/103 vs
183/112). All three with increased risks but only one of four
with decreased risks had a diagnosis of superimposed PE.
DISCUSSION
The angiogenic factors sFlt1 and PlGF are strongly associated
with adverse maternal and fetal outcomes in the early third
trimester,23,24,33 and the sFlt1/PlGF ratio is correlated with
diagnosis and outcomes.23,30,34,35 In our dataset, 73% of all
severe outcomes were associated with an elevated sFlt1/PlGF
ratio (≥85). False positive rates were similar. The current study
is the ﬁrst to create a validated risk-based model for predicting
severe adverse pregnancy outcomes speciﬁcally calibrated for
the PE triage setting. The detection rate increased to 77% using
a validated model reporting patient-speciﬁc risks. Obstetricians
are already familiar with the patient-speciﬁc risks widely used
in prenatal for Down syndrome screening.36 Our analyses
demonstrate that a simple bivariate model can reliably predict
an individual’s risk of a severe adverse pregnancy outcome
among women being evaluated for PE.
Patient-speciﬁc risks might be helpful in at least three ways.
For high-risk patients, it informs decision-making regarding
transfer to a higher level facility in anticipation of preterm
delivery and betamethasone treatment, potentially reducing
morbidity from delay in identiﬁcation. These women might
also be candidates for new treatments that address the
underlying angiogenic imbalance.14 For low-risk patients, the
information aids in offering expectant management that could
result in reduced hospital admission, outpatient evaluations
and, perhaps, preterm deliveries. Subsequent testing every
2weeks would be aimed at reﬁning the risks as the pregnancy
continues. Patient-speciﬁc risks could also aid management
decisions involving patients with underlying disorders (e.g. renal
disease, chronic hypertension, diabetes).37,38 Modeling also
addresses the difﬁculty in interpreting sFlt1/PlGF ratios that
are negative but relatively high (e.g. 70) and can reduce the
Figure 4 Patient-speciﬁc risk of an angiogenesis-related severe
outcome versus gestational age at delivery. This ﬁgure shows the
patient-speciﬁc risks assigned by the sFlt1 and PlGF model, applied
to data from the referent and severe outcome groups. The model’s
risk of a severe outcome (logarithmic x-axis) is centered on the
population baseline risk (1 : 2), with vertical dotted lines at 10-fold
increases (right side) and 10-fold reductions (left side) in risk. From
left to right, these three groups are considered to be low, intermediate
and high risk. The decimal gestational age at delivery (y-axis) has a
horizontal dashed line at 37.0weeks, the cutoff used to delineate
premature and term delivery. Severe outcomes are shown as small
ﬁlled circles, while the referent pregnancies are shown as large open
circles. Figure 4A shows results from the modeling dataset, Figure 4B
from the validation dataset and Figure 4C from the combined
dataset/model. In Figure 4C, a white dash (–) indicates those that are
ACOG negative for PE among those with severe outcomes (ﬁlled red
circles). A black plus (+) indicates an ACOG positive for PE among
those with referent outcomes (open green circles)
Figure 5 Comparison of the sFlt1/PlGF ratio with the patient-speciﬁc
modeled risks based on sFlt1 and PlGF measurements expressed as
multiples of the median (MoM). These data are from the entire cohort
using the combined model. Risks are capped at 100-fold decrease
(or increase) in the baseline risk (r2 = 0.93)
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anxiety associated with physician interpretation of raw
numbers. A consistent risk estimate for severe outcomes
may also reduce practice variation.
Another advantage of modeling is the ability to explicitly
incorporate additional risk factors to aid in the prediction of
severe outcomes associated with angiogenic dysfunction. For
example, we found that lighter women (<170 lb) are twice as
likely to have a severe outcome as heavier women. This might
be because of the association between maternal weight and
hypertension that increases the chance for heavier women to
be referred to PE triage. However, the related severe adverse
outcomes associated with angiogenic dysfunction actually
appear to be less common in these heavier women; a preliminary
ﬁnding that requires conﬁrmation.
Our study has limitations. Data were collected from a single
institution, but sufﬁcient information was provided so our model
could be applied to existing data from other high-risk cohorts.
This could provide conﬁrmation and transferability of our results.
Because our study was observational, it was not possible to
categorize all enrolled pregnancies as having a referent or severe
outcome as a result of the potential impact of a PE diagnosis on
delivery timing. Our analyses did not include a direct comparison
with the diagnosis of PE because of this potentially strong bias.
This may become even more of an issue with the new ACOG
criteria.10 Our model is not directly applicable to the general
population, where the prior risks of PE are much lower. Lastly, it
was not possible to serially follow all of the pregnancies every
2 weeks to look at longer term results, as only a subset of women
were re-enrolled later in pregnancy.
Our study models late second through early third-trimester
sFlt1 and PlGF measurements reported in MoM. In this
respect, it is similar to the approach used in a large general
population cohort of women at background risk for PE.39 Our
model, however, provides a validated patient-speciﬁc risk
rather than a positive or negative interpretation and allows
providers to incorporate additional information into decision-
making. Enrollment for our high-risk cohort includes
enrollment prior to 34weeks, and we chose to predict severe
adverse outcomes rather than the diagnosis of PE. Although
these differences in design and analyses are important, both
studies ﬁnd that the angiogenic factors are capable of
identifying women for whom more or less intensive
interventions may be warranted. It is now time to undertake
randomized trials that could avoid issues related to our
unclassiﬁed category and provide for serial testing of women
every 2weeks until 34.0weeks’ gestation. Implementation of
such a model in a practice setting could provide evidence that
most severe outcomes can be identiﬁed and treated and that
lower rates of preterm deliveries, improvement of resource
allocation and reduced costs can be achieved.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Angiogenic factors are associated with preeclampsia (PE), a
pregnancy-speciﬁc syndrome that can lead to severe adverse
outcomes. The sFlt1/PlGF ratio has been shown to identify patients
at risk for preeclampsia.
WHAT DOES THIS STUDY ADD?
• We deﬁne the disorder of interest as any severe adverse outcome
among women with suspected PE. Angiogenic test results are
combined into patient-speciﬁc risks to optimize translation to patient
care to improve overall pregnancy outcomes.
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